DM102

DM102 is a novel synthetic small molecule inhibitor of acid ceramidase (AC), an enzyme that hydrolyzes the pro-apoptotic lipid ceramide into sphingosine and free fatty acids. Developed through a collaboration between the Spanish National Research Council (CSIC) and the John Wayne Cancer Institute, DM102 acts as a substrate mimic to selectively block acid ceramidase activity, leading to an accumulation of intracellular ceramide and the induction of cell cycle arrest and apoptosis. Preclinical studies have demonstrated that DM102 exhibits synergistic anticancer activity when combined with ceramide-generating agents, such as C6-ceramide or fenretinide (4-HPR), in breast and prostate cancer models.

Other names

(2R,3Z)-N-(1-hydroxyoctadec-3-en-2-yl)pivalamide(R,E)-N-(1-hydroxyoctadec-3-en-2-yl)pivalamideE-tb